investiment.io
Rani Therapeutics Holdings, Inc.
$2.12
-1.06 (-33.33%)
Rani Therapeutics Holdings, Inc.
$2.12
-1.06 (-33.33%)
RANI Price Chart
| Basic | |
|---|---|
| Market Cap | $112.69M |
| Price | $2.12 |
| 52 Week Range | 1.82-8.75 |
| Beta | 0.17 |
| Margins | |
| Gross Profit Margin | 56.07% |
| Operating Profit Margin | -2103.53% |
| Net Profit Margin | -1112.11% |
| Valuation (TTM) | |
| P/E Ratio | -1.82 |
| Price to Sales Ratio | 40.73 |
| Price to Book Ratio | 19.68 |
| PEG Ratio | -0.21 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
140
IPO Date
2021-07-30T00:00:00.000Z
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Phone
408 457 3700
Address
2051 Ringwood Avenue, San Jose, CA, 95131, US
CIK
0001856725